Moderna (MRNA) posted a third-quarter net loss of $200 million compared to net income of $13 million, last year. Loss per share was $0.51 compared to profit of $0.03. Analysts on average expected the company to report a loss per share of $2.18, for the quarter. Analysts' estimates typically exclude special items.
Net product sales were $973 million compared to $1.82 billion, prior year. Total revenue declined to $1.02 billion from $1.86 billion. Total revenue declined 45% primarily driven by a 47%, decrease in net product sales, mainly due to lower COVID vaccine sales.
For 2025, the company now expects total revenue in a range of $1.6 - $2.0 billion, narrowed from previous guidance range of $1.5 - $2.2 billion. The company projects fourth quarter revenue in a range of $0.3 - $0.7 billion.
The company's cash, cash equivalents and investments as of September 30, 2025, were $6.6 billion.
Shares of Moderna are up 9% in pre-market trade on Thursday. For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.